人工孤雌生殖能否避开人类治疗性克隆中的伦理陷阱？历史视角。
Can artificial parthenogenesis sidestep ethical pitfalls in human therapeutic cloning? An historical perspective.
作者信息
Fangerau H
机构信息
Institute for the History of Medicine, Heinrich-Heine University Düsseldorf, Universitaetsstrasse 1, 40225 Düsseldorf, Germany.
出版信息
J Med Ethics. 2005 Dec;31(12):733-5. doi: 10.1136/jme.2004.010199.
The aim of regenerative medicine is to reconstruct tissue that has been lost or pathologically altered. Therapeutic cloning seems to offer a method of achieving this aim; however, the ethical debate surrounding human therapeutic cloning is highly controversial. Artificial parthenogenesis-obtaining embryos from unfertilised eggs-seems to offer a way to sidestep these ethical pitfalls. Jacques Loeb (1859-1924), the founding father of artificial parthenogenesis, faced negative public opinion when he published his research in 1899. His research, the public's response to his findings, and his ethical foundations serve as an historical argument both for the communication of science and compromise in biological research.
再生医学的目的是重建已丧失或发生病理改变的组织。治疗性克隆似乎提供了一种实现这一目标的方法；然而，围绕人类治疗性克隆的伦理辩论极具争议性。人工孤雌生殖——从未受精卵中获取胚胎——似乎提供了一条避开这些伦理陷阱的途径。人工孤雌生殖的创始人雅克·勒布（1859 - 1924）在1899年发表其研究成果时面临着负面的公众舆论。他的研究、公众对其发现的反应以及他的伦理基础，构成了关于科学传播和生物学研究中妥协的一个历史论据。
Zotero 插件